CTNNB1 and neoplasm: There were no differences in the incidences of CTNNB1 mutation between 7 tumours with IGF2-LOI and 29 tumours with IGF2-ROI or 12 tumours with IGF2-LOH, and between 29 tumours with IGF2-ROI and 12 tumours with IGF2-LOH.